Podcasts about neotract

Ingenion Medical, run by our guest Ed Cappabianca, is going to change the standard catheter in the UK - The Foley catheter. Urinary catheter-associated infections kill 2,100 people a year and block 1.2 million hospital bed-days. And yet, the Foley catheter - the standard of care - has barely changed in 91 years. Ingenion Medical has built what replaces it.The cymactive™ 2.0R is a CE-marked, patient-controlled urethral catheter with a patented magnetic valve that is already in clinical use across the UK and 15 international markets. It is superior to either standard Foleys or intermittent catheters, and generates revenue today. Ingenion Medical are seeking investors. Here's the Investment case:• Revenue generative, regulatory approved. CE Mark achieved Q1 2024. ISO 13485 renewed October 2025. FDA pre-sub meeting completed.• Commercial traction. Distributor agreements in over 10 countries. NHS Supply Chain at contract award stage. 15 NHS hospitals active or in pipeline.• Profitable at 1,600 patients per month (80 urologists x 20 patients). Breakeven H2 2027. £49m revenue projected 2030.• Exit precedent. Comparable urology acquisitions: Urotronic > Laborie $600m;Neotract > Teleflex $1.1b; Augmenix > Boston Scientific $600m; .• World-class advisors. Advisory board includes: Professor Chris Chapple (former European Association of Urology Secretary General) and Professor Kurt Naber, global authority on urinary tract infections.If you would like the detailed Investor Pitch Deck, go to: ingenion.approvedinvestors.co.ukSummary of PodcastKey TakeawaysThe Problem: Current catheters cause frequent, costly infections (£2k–£3.5k per cycle for the NHS) and severely limit patient mobility and quality of life.The Solution: Ingenion's cymactive catheter is a 30-day, self-voiding device with no external bag, restoring patient dignity and designed to reduce infection risk.Market Validation: The NHS created a new framework channel specifically for SimActive, signaling strong support for its innovation and cost-saving potential.The Ask: Ingenion is raising £2M (for ~10% equity) to fund commercialisation, targeting a future trade sale to a major urology firm for a potential 10x investor return.The Problem with Current CathetersUrinary Retention: A common condition caused by issues like BPH (enlarged prostate), Parkinson's, MS, and spinal cord injuries.Foley Catheter (Indwelling):The 100-year-old standard, anchored by an internal balloon.Creates a "superhighway for bacteria," causing frequent, costly infections.Full cost of ownership for the NHS is ~£800/month per patient.Intermittent Catheters (Single-Use):Used 5–8 times daily, creating significant waste and inconvenience.Account for 90% (£157.5M) of the NHS's £175M annual catheter spend.Patient Impact:Fear of infection and public voiding → social isolation.Reduced fluid intake → dehydration, which can worsen conditions like dementia.The cymactive SolutionInnovation: A 30-day, self-voiding catheter with no external tubes or bags.Mechanism:An internal, patient-controlled magnetic valve.An external magnet opens the valve; removing it allows the valve to close naturally.Infection Defense:The urethra seals over the valve's end, mimicking the body's natural defense against bacteria.Anecdotal evidence suggests reduced infections and restored function.Product Pipeline:Current: cymactive for male urinary retention (CE marked).In Development: Versions for women and for male incontinence.Market Validation & CommercialisationNHS Adoption:The NHS created a new framework channel for cymactive, as it didn't fit existing categories.Ingenion was the sole applicant and signed a 2-year contract on March 12, 2026.Ordering codes are now live for hospitals.Go-to-Market Strategy:Goal: Build awareness among clinicians and patient groups.Method: Target early adopters and use their case studies, shared by the NHS innovation team, to drive broader adoption.Rationale: A randomised control trial was unfeasible because Foley catheter users were unwilling to risk being randomised to the control group.Investment OpportunityThe Ask: £2M for ~10% equity (pre-money valuation: £18M).Exit Strategy: Trade sale to a major urology firm (e.g., Coloplast, Becton Dickinson).Rationale: Leverage a large firm's infrastructure for rapid, global scaling.Target Return: A typical venture capital return of ~10x investment.Investor Profile: High Net Worth (HNW) or Sophisticated Investors.Due Diligence: Pitch deck available at ingenion.approvedinvestors.co.ukThe Next 100 Days Podcast Co-HostsGraham ArrowsmithGraham founded Finely Fettled in 2014 to provide data from The UK High Net Worth Database to marketers targeting affluent and high-net-worth customers. He's the founder of MicroYES, a Partner for MeclabsAI, creating lead generation AI Agents & Workflows and introducing the MeclabsAI Platform. Graham also provides an Answer Engine Optimisation solution to get your website in shape to be found by LLMs.Kevin ApplebyKevin specialises in finance transformation and implementing business change. He's the COO of GrowCFO, which provides both community and CPD-accredited training designed to grow the next generation of finance leaders. You can find Kevin on LinkedIn and at kevinappleby.com

Jason Elmore is the Sr. Manager of Sales and Training Development at NeoTract. With extensive experience in med device startups as well as with the world’s largest medical device and pharmaceutical companies, he knows a thing or two about the patient journey. In this episode, Jason enlightens us on the increasingly popular concept of shared decision making in medicine — and tells us how becoming a key player in the patient’s clinical pathway is one of the best things a MedTech sales rep can do. In this episode, you’ll learn: Why the patient should have a hand in selecting their treatment pathway How to make your medical professional customers “teachers” so they can better interact with their patients The importance of tracking and celebrating your results Why you’re missing an opportunity if you haven’t rethought and adjusted your value proposition for the COVID environment Plus, we create a diagnostic tool to show MedTech reps what to look for when assessing the clinical pathway. Resources and links from the show: Connect with Jason Elmore on LinkedIn Connect with Clark Wiederhold on LinkedIn Connect with Zed Williamson on LinkedIn The Growth-Driven Practice Series The Behavior Change Blueprint Elite Execution: Disciplines & Insights for Extraordinary Salespeople by Jason Elmore

Josh Makower, General Partner, New Enterprise Associates Josh Makower is a General Partner on NEA's healthcare team leading their medtech/healthtech practice. Josh is also the Founder and Executive Chairman of ExploraMed, a medical device incubator that has created 8 companies over the past 20 years. Notable transactions from the ExploraMed portfolio include NeoTract, acquired by Teleflex in 2017, Nuelle, acquired by Aytu in 2017, Acclarent, acquired by J&J in 2009, EndoMatrix, acquired by C.R. Bard in 1997 and TransVascular, acquired by Medtronic in 2003. On-going ExploraMed/NEA ventures include Moximed, Willow and Exploramed V. In addition to his role at NEA, Josh serves on the faculty of the Stanford University Medical School as a Consulting Professor of Medicine and is Co-Founder of Stanford's Biodesign Innovation Program. Josh currently serves on the board of directors for DOTS Devices, Eargo, ExploraMed, Intrinsic Therapeutics, Moximed, Willow, SetPoint Medical and Coravin. Josh holds over 300 patents and patent applications for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery, obesity, orthopedics, women's health, and urology. He received an MBA from Columbia University, an MD from the NYU School of Medicine, and a bachelor's degree in Mechanical Engineering from MIT.

In this Medtech Talk Podcast, CEO John Pedersen explains why he chose to help Augmenix roll out its SPACEOAR implant, a hydrogel that's inserted between a patient's prostate and rectum to save healthy tissue from radiation exposure. In this talk, Pedersen discusses the rise of urology - which includes the recent acquisitions of Neotract and NxThera. He also updates listeners on Augmenix's efforts to secure reimbursement. Finally, the former Boston Scientific exec offers advice to anyone working in a global Medtech company.

Join us on Thursday at the Medtech Conference in Minneapolis to hear from Congressman Erik Paulsen. A longtime proponent of the Medtech industry, Rep. Paulsen most recently co-authored a letter asking the Trump administration to remove medical technology products from a list of Chinese imports subject to protective tariffs. The five-term Congressman also has fought against the Medical Device Tax. The Medtech Conference co-chairs and advisory board also are pleased to honor Dave Amerson, CEO of NeoTract, as the recipient of this year’s Dealmaker of the Year Award. The award recognizes Amerson's leadership of the urology start-up as it established its UroLift System as a critical treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Sales of UroLift were surging when Teleflex agreed to acquire the company, paying $725 million up front with the promise of another $375 million in milestone payments over the next two years. In an interview, Justin Klein, general partner of NEA, and Amerson will discuss: The steps Neotract took to adopt a winning culture? What strategies helped the company secure support from payers, providers? How the deal with Teleflex came to be? What's next for Teleflex in Urology? Join us on May 31st to explore this singular successful story and to better understand our entire Medtech sector.

Exits Johnson & Johnson is celebrating an exit with the acquisition of its portfolio company NeoTract by Teleflex for a total consideration of $1.1bn. Intel Capital also celebrated an exit as its portfolio company StarCash, a digital gift card service, was acquired by fintech company Blackhawk Network for $175m in cash. Madsack hails CleverShuttle Paytm to make … Continue reading "11 September 2017 – Judging Purchase Versus Investment"

Biz Stone, the co-founder of Twitter, has famously stated, “Timing, perseverance, and 10 years of trying will eventually make you look like an overnight success.” In the world of medtech startups, this is almost always the case. And it’s certainly true with UroLift, a device that came to life in the fall of 2004...[read more]Related StoriesWhy Intersect ENT is an Example of Hope for the Medtech IndustryAre Medical Device Models the Key to Building a Lean Medtech Startup?How Will These 2 Major Healthcare Changes Affect Medical Device Companies?